SWA
CPRX

Sutton Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Sutton Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$175 Hold
15
– – ﹤0.01% 843
2023
Q2 		$202 Buy
+15
New +$216 ﹤0.01% 832
2023
Q1 		– Sell
-867
Closed -$16.1K – 979
2022
Q4 		$16.1K Buy
867
+860
+12,286% +$13.2K 0.01% 782
2022
Q3 		$90 Buy
+7
New +$83 ﹤0.01% 1618

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sutton Wealth Advisors's CPRX Position: Q3 2023 in Review

Sutton Wealth Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q3 2023 at 15 shares worth $175. The position accounts for ﹤0.01% of the portfolio, ranked #843.

Sutton Wealth Advisors first reported a position in CPRX in Q3 2022 and has held it in 4 quarters since. The position peaked at $16.1K in Q4 2022. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Sutton Wealth Advisors held 15 shares of Catalyst Pharmaceutical worth $175 as of Q3 2023.
  • Sutton Wealth Advisors left its Catalyst Pharmaceutical share count unchanged in Q3 2023.
  • Catalyst Pharmaceutical made up ﹤0.01% of Sutton Wealth Advisors's portfolio in Q3 2023, its #843 holding.
  • Sutton Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 4 quarters since.
  • Sutton Wealth Advisors's Catalyst Pharmaceutical position peaked at $16.1K in Q4 2022.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Sutton Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.